6-喹啉羧酸甲酯 | 38896-30-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-喹啉羧酸甲酯
• 中文别名: 喹啉-6-甲酸甲酯；6-喹啉甲酸甲酯
• 英文名称: 6-(methoxycarbonyl)quinoline
• 英文别名: methyl quinoline-6-carboxylate；quinoline-6-carboxylic acid methyl ester；methyl 6-quinolinecarboxylate
• CAS: 38896-30-9
• 化学式: C₁₁H₉NO₂
• mdl: MFCD00956766
• 分子量: 187.198
• InChiKey: XSRWQTDEIOHXSL-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C
• 沸点：
  315.1±15.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  常规情况下不会分解，没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封、阴凉、干燥保存。

SDS

Name:	Methyl quinoline-6-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	38896-30-9

Section 1 - Chemical Product MSDS Name:Methyl quinoline-6-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
38896-30-9	Methyl quinoline-6-carboxylate	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 38896-30-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 85 - 86 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H9NO2
Molecular Weight: 187

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 38896-30-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl quinoline-6-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 38896-30-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 38896-30-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 38896-30-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-喹啉羧酸甲酯 在 双氧水 、 苯甲酰氯 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 3.0h， 生成 2-氰基喹啉-6-羧酸甲酯
  参考文献：
  名称：

  新型芬太尼杂合衍生物的合成和药理研究，该衍生物在μ阿片受体和I2-咪唑啉结合位点具有活性。

  摘要：

  带有有效I2-咪唑啉结合位点（IBS）配体（即胍和BU224部分）的芬太尼衍生的两个杂化分子系列，与脂族（m = 2、3、4、6、7、8、9和12亚甲基）连接制备）或芳族间隔基。通过对人死后脑膜的竞争结合研究，确定它们对μ阿片受体和I2-IBS的亲和力。BU224杂合分子在微摩尔至低微摩尔范围内与μ阿片受体和I2-IBS结合，而链烷胍系列在这两个受体的纳摩尔范围内均表现出显着的亲和力。[35S] GTPgammaS功能测定是在人死后脑膜上进行的，每个系列的选定配体（4f和8g）均显示出对μ阿片受体和I2-IBS亲和力的最高双重亲和力。两种化合物都显示出激动剂特性：在链烷胍衍生物4f的mu阿片受体上（间隔：六个亚甲基单元）和在G蛋白偶联受体（GPCR）上仍需测定8g。缺乏体内4f的镇痛特性（即在小鼠中进行热板试验和扭体试验），与良好的体外结合数据（Ki mu = 1.04 +/- 0.28 nM，Ki

  DOI：

  10.1016/j.bmc.2006.06.007
• 作为产物：
  描述：

  6-(methoxycarbonyl)quinoline 1-oxide 在 10-phenyl-9-(2,4,6-trimethylphenyl)acridinium tetrafluoroborate 、 二异丙胺 作用下， 以 乙腈 为溶剂， 以83 %的产率得到6-喹啉羧酸甲酯
  参考文献：
  名称：

  氮杂芳基氮氧化物的无金属可见光催化脱氧：利用光子进行高效的绿色合成

  摘要：

  缺电子氮杂芳烃的区域选择性和化学选择性官能化通常需要将其转化为相应的N-氧化物，并随后在官能化后去除氧以得到所需的取代的氮杂芳烃。使用吖啶基有机光催化剂在蓝色 LED 光下开发了一种高效的无金属可见光光氧化还原催化氮杂环化合物N氧化物脱氧的方法。该方法的高效性和温和性已通过多种具有反应性官能团的氮杂环N-氧化物的较高脱氧产率得到证明。光催化还原的稳健性已通过将反应轻松放大至克级而得到证明，且反应产率没有太大变化。

  DOI：

  10.1002/asia.202400147

文献信息

• [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2009151991A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• 四氢苯并噻吩化合物
  申请人：广东东阳光药业有限公司

  公开号：CN105524053B

  公开（公告）日：2020-06-05

  本发明的目的在于提供具有肠道磷酸转运蛋白(NPT‑IIb)抑制作用、作为高磷血症的治疗剂和/或预防剂的有效成分的四氢苯并噻吩化合物或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、酯、药学上可接受的盐或它的前药和药物组合物。
• [EN] FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRODIOXINE FUSIONNÉS À UTILISER EN TANT QU'INHIBITEURS DE FACTEUR DE TRANSCRIPTION 1 DU CHOC THERMIQUE
  申请人：CANCER REC TECH LTD

  公开号：WO2015049535A1

  公开（公告）日：2015-04-09

  The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A1、A2、R4和Q如本文所定义。本发明的化合物是热休克因子1（HSF1）的抑制剂。具体来说，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。
• Phosphoric Acid Mediated Light‐Induced Minisci C−H Alkylation of <i>N</i> ‐Heteroarenes
  作者：Songyang Jin、Xinxin Geng、Yujun Li、Ke Zheng

  DOI：10.1002/ejoc.202001538

  日期：2021.2.12

  A visible light‐intduced/phosphate‐mediated light‐induced Minisci‐type reaction under metal‐ and photocatalyst‐free condition was developed, which provided an efficient and environmentally friendly way to access functionalized N‐heteroarenes. The transformation underwent a radical pathway, and the diphenyl phosphate played a key role in the catalytic cycle via hydrogen bonding.

  在无金属和无光催化剂的条件下，开发了可见光诱导/磷酸盐介导的光致Minisci型反应，这为获得功能化的N-杂芳烃提供了一种有效且环保的方法。转化经历了自由基途径，而磷酸二苯酯通过氢键在催化循环中起着关键作用。
• INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
  申请人：Praxis Biotech LLC

  公开号：US20190185451A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

  描述了用于调节成纤维细胞活化蛋白（FAP）的化合物和组合物。这些化合物和组合物可能被用作治疗疾病的治疗剂，包括高增殖性疾病。

表征谱图